CleanSpace Holdings Limited (ASX:CSX) Progresses Global Respiratory Technology Growth Strategy

Sonal Goyal

23 September 2026 08:36 PM AEST

CleanSpace Holdings Limited (ASX:CSX) Progresses Global Respiratory Technology Growth Strategy

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue remained broadly stable at $19.8 million while gross Margin was maintained at 75%.
CleanSpace launched AGILE, a loose-fitting powered air-purifying respirator designed for broader workplace applications.
Europe revenue increased 8% during FY26, supported by France and Nordic market performance.
Cash at bank was $10.1 million at 30 June 2026, supporting continued Investment in growth initiatives.

CleanSpace Holdings Limited (ASX:CSX) is an Australian technology company that designs, manufactures and sells advanced respiratory protection solutions for industrial and healthcare markets. The company develops powered respirator systems using its proprietary AirSensit® technology to support workers operating in hazardous environments. During FY26, CleanSpace focused on strengthening its global distribution network, advancing product innovation and launching AGILE, its next-generation loose-fitting powered air-purifying respirator.

FY26 Performance Reflects Stable Revenue and Strategic Investment

CleanSpace reported revenue of $19.8 million for FY26, representing growth of 0.3% compared with the previous year. The company maintained gross margin at 75%, supported by pricing initiatives, production efficiencies and cost management.

The company reported an operating EBITDA loss of $0.6 million, reflecting increased investment in research and development, sales and Marketing activities and systems upgrades. Research and Development expenses increased as CleanSpace progressed product innovation programs, including AGILE development and certification.

The statutory loss after tax attributable to owners was $1.25 million compared with a loss of $0.48 million in the previous year.

CleanSpace ended FY26 with cash at bank of $10.1 million. The balance reflected continued investment in sales capability, marketing initiatives, research and development and implementation of a new enterprise resource planning system.

The company’s product mix remained balanced, with respirators contributing 54% of revenue and consumables, accessories and other products contributing 46%.

AGILE Launch Expands Respiratory Protection Platform

CleanSpace introduced AGILE during FY26 as a new loose-fitting powered air-purifying respirator based on the company’s AirSensit® breath-responsive technology.

The product was developed in response to changing workplace requirements, including increased focus on respiratory protection standards and the challenges associated with traditional tight-fitting respirators.

AGILE received certification in Europe and Australia/New Zealand during FY26, expanding CleanSpace’s ability to address additional markets including mining, infrastructure, construction and quarrying.

The company stated that AGILE removes some limitations associated with fit-testing requirements while maintaining CleanSpace’s lightweight design principles and powered respiratory protection approach.

Following certification, CleanSpace reported early customer interest and product trials, with initial sales activity in targeted regions.

The company continues investing in product development, certification capability and future respiratory technology programs.

Global Market Development and FY27 Priorities

Regional performance varied during FY26. Europe was the largest contributor, generating $12.9 million in revenue and increasing 8% compared with the previous year. France continued to expand through distributor relationships and key account growth, while Nordic markets also contributed growth.

APAC and Rest of World revenue was $4.7 million, broadly stable compared with FY25. The region experienced purchasing delays due to regulatory changes and operational disruptions in some markets, while CleanSpace expanded distributor relationships and secured AGILE certification in Australia/New Zealand.

North America revenue declined to $2.2 million as regulatory uncertainty and delayed purchasing decisions affected market activity. Despite these conditions, CleanSpace expanded distributor coverage and developed opportunities in first responder and industrial markets.

For FY27, CleanSpace plans to focus on commercialising AGILE, expanding distributor networks, strengthening enterprise customer relationships and continuing investment in sales, marketing, research and development.

The company is also progressing its longer-term strategy of combining connected respiratory devices with smart data capabilities to support customer compliance and operational insights.

Key Insights

CleanSpace is advancing its respiratory technology platform through product innovation, global market expansion and the launch of AGILE. FY26 focused on maintaining financial discipline while building commercial capability, strengthening distribution channels and preparing for future growth opportunities.

FAQs

Q:What does CleanSpace Holdings do?

A:CleanSpace designs and manufactures respiratory protection solutions for industrial and healthcare markets.

Q:What is AGILE?

A:AGILE is a loose-fitting powered air-purifying respirator developed using CleanSpace’s AirSensit technology.

Q:What was CleanSpace revenue in FY26?

A:CleanSpace reported FY26 revenue of $19.8 million.

Q:Which region contributed the most revenue in FY26?

A:Europe was the largest regional contributor with revenue of $12.9 million.

Q:What are CleanSpace’s FY27 priorities?

A:The company is focused on AGILE commercialisation, distributor expansion, enterprise customer growth and continued innovation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.